Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
47,559,740
-
Total 13F shares
-
1,923,874
-
Share change
-
-285,678
-
Total reported value
-
$3,369,565
-
Price per share
-
$1.76
-
Number of holders
-
25
-
Value change
-
-$378,633
-
Number of buys
-
9
-
Number of sells
-
8
Institutional Holders of SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS) as of Q2 2025
As of 30 Jun 2025,
SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS) was held by
25 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,923,874 shares.
The largest 10 holders included
BVF INC/IL, Sessa Capital IM, L.P., VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, Pathstone Holdings, LLC, Kovitz Investment Group Partners, LLC, First PREMIER Bank, CITADEL ADVISORS LLC, Kestra Advisory Services, LLC, and Creative Planning.
This page lists
25
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.